Anti-Human CD40/TNFRSF5 Reference Antibody|抗人CD40/TNFRSF5参考抗体(靶标：人CD40)
- 货号：RB9THB782316
- 价格：面议
- 点击：298
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG1-kappa |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40 |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | P25942 |
| 背景信息 | Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. In a recent multicenter, randomized control trial (NCT02217410), with the primary endpoint of non-inferiority on the composite endpoint, iscalimab therapy showed non-inferiority on a composite clinical endpoint, improved renal function, reduced risk for new onset diabetes and similar safety compared with tacrolimus. The analysis presented at the ATC included patients from this study that underwent either routine biopsies or biopsies as part of a follow-up protocol. The data was reviewed and scored by a blinded pathologist using the established Banff criteria and CADI. A CADI of 1 or less was considered as 'normal renal histology'. The average CADI at final biopsy was 1.6 ±0.6 for iscalimab and 5.1 ±0.8 for tacrolimus. |
| 别名 | 2642171-59-1 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
相关产品: